Repealed and added by Stats. 2025, Ch. 21, Sec. 43. (AB 116) Effective June 30, 2025.
In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
(a)For over-the-counter naloxone products. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
(b)For generic or brand name drugs to address emerging health concerns, including in reproductive health care or gender affirming
health care.
(c)For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
(d)For the manufacture, purchase, or distribution of medical supplies or medical devices.
Cite this section